Movement Alert｜Sino Biopharmaceutical Rises 3.72% in Regular Trading, TRD205 Granted Breakthrough Therapy Designation Plus Morgan Stanley Raises Earnings Estimates

Market Focus07-15 09:55

On July 15, Sino Biopharmaceutical rose 3.72% in regular trading, trading at HKD 5.32/share, with turnover of HKD 108 million.

On the news front, the company announced on July 14 that its subsidiary Beijing Tide Pharmaceutical's independently developed Class 1 new drug TRD205 has completed a Phase II clinical trial for chronic post-surgical neuropathic pain (CPSNP) and was granted Breakthrough Therapy Designation by the CDE based on positive data. The drug acts only on the peripheral nervous system, potentially avoiding common adverse effects of CNS-targeting agents, and there is currently no approved therapy specifically for CPSNP.

Separately, Morgan Stanley on July 14 raised its basic EPS estimates for Sino Biopharmaceutical by 13.6%, 5.5%, and 3.9% for 2026-2028 respectively after factoring in licensing income from Sanofi and GSK upfront payments, while reiterating an Overweight rating with a target price of HKD 7.8.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168965549?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168965549","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Sino Biopharmaceutical Rises 3.72% in Regular Trading, TRD205 Granted Breakthrough Therapy Designation Plus Morgan Stanley Raises Earnings Estimates","media":"Market Focus","content":"<p><p>On July 15, Sino Biopharmaceutical rose 3.72% in regular trading, trading at HKD 5.32/share, with turnover of HKD 108 million.</p><p>On the news front, the company announced on July 14 that its subsidiary Beijing Tide Pharmaceutical's independently developed Class 1 new drug TRD205 has completed a Phase II clinical trial for chronic post-surgical neuropathic pain (CPSNP) and was granted Breakthrough Therapy Designation by the CDE based on positive data. The drug acts only on the peripheral nervous system, potentially avoiding common adverse effects of CNS-targeting agents, and there is currently no approved therapy specifically for CPSNP.</p><p>Separately, Morgan Stanley on July 14 raised its basic EPS estimates for Sino Biopharmaceutical by 13.6%, 5.5%, and 3.9% for 2026-2028 respectively after factoring in licensing income from Sanofi and GSK upfront payments, while reiterating an Overweight rating with a target price of HKD 7.8.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Sino Biopharmaceutical Rises 3.72% in Regular Trading, TRD205 Granted Breakthrough Therapy Designation Plus Morgan Stanley Raises Earnings Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Sino Biopharmaceutical Rises 3.72% in Regular Trading, TRD205 Granted Breakthrough Therapy Designation Plus Morgan Stanley Raises Earnings Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Sino Biopharmaceutical rose 3.72% in regular trading, trading at HKD 5.32/share, with turnover of HKD 108 million.</p><p>On the news front, the company announced on July 14 that its subsidiary Beijing Tide Pharmaceutical's independently developed Class 1 new drug TRD205 has completed a Phase II clinical trial for chronic post-surgical neuropathic pain (CPSNP) and was granted Breakthrough Therapy Designation by the CDE based on positive data. The drug acts only on the peripheral nervous system, potentially avoiding common adverse effects of CNS-targeting agents, and there is currently no approved therapy specifically for CPSNP.</p><p>Separately, Morgan Stanley on July 14 raised its basic EPS estimates for Sino Biopharmaceutical by 13.6%, 5.5%, and 3.9% for 2026-2028 respectively after factoring in licensing income from Sanofi and GSK upfront payments, while reiterating an Overweight rating with a target price of HKD 7.8.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1168965549","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168965549","pubTimestamp":1784080521,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Sino Biopharmaceutical rose 3.72% in regular trading, trading at HKD 5.32/share, with turnover of HKD 108 million.On the news front, the company announced on July 14 that its subsidiary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"走势提醒|中国生物制药常规交易上涨3.72%，TRD205获突破性疗法认定，摩根士丹利上调盈利预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"On July 15, Sino Biopharmaceutical rose 3.72% in regular trading, trading at HKD 5.32/share, with turnover of HKD 108 million.On the news front, the company announced on July 14 that its subsidiary Beijing Tide Pharmaceutical's independently developed Class 1 new drug TRD205 has completed a Phase II clinical trial for chronic post-surgical neuropathic pain (CPSNP) and was granted Breakthrough Therapy Designation by the CDE based on positive data. The drug acts only on the peripheral nervous system, potentially avoiding common adverse effects of CNS-targeting agents, and there is currently no approved therapy specifically for CPSNP.Separately, Morgan Stanley on July 14 raised its basic EPS estimates for Sino Biopharmaceutical by 13.6%, 5.5%, and 3.9% for 2026-2028 respectively after factoring in licensing income from Sanofi and GSK upfront payments, while reiterating an Overweight rating with a target price of HKD 7.8.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168965549","isCrawlerRequest":true}